Market Closed -
Nasdaq Stockholm
11:29:44 2024-04-29 am EDT
5-day change
1st Jan Change
199
SEK
+0.76%
+7.80%
-25.69%
Sales 2024 *
502M
45.93M
Sales 2025 *
1.01B
92.34M
Capitalization
17.58B
1.61B
Net income 2024 *
16M
1.46M
Net income 2025 *
454M
41.5M
EV / Sales 2024 *
33.3
x
Net cash position
2024
*
838M
76.56M
Net cash position
2025
*
1.17B
107M
EV / Sales 2025 *
16.2
x P/E ratio 2024 *
1,000
x
P/E ratio 2025 *
38.8
x
Employees
88
Yield 2024 *
-
Yield 2025 *
-
Free-Float
44.12%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Actualización de las fuertes variaciones del día: El lujo, ALD, Aperam, SBB, Entain, Bioarctic y otras
23-09-25
Les actions en mouvement : le luxe, ALD, Aperam, et d'autres
23-09-25
EN DIRECTO DESDE LOS MERCADOS: Clariant, LDC, Samsung Electronics, AbbVie, UBS, Sika, Novo Nordisk, LVMH...
23-07-07
Est-ce que la Fed va tout casser ?
23-07-07
En Direct des Marchés : Stellantis, Carrefour, Samsung, Clariant, Meta, LDC, Coloplast...
23-07-07
More news 1 day +0.76%
1 week +7.80%
Current month -7.61%
1 month -7.61%
3 months -13.85%
6 months -8.63%
Current year -25.69%
More quotes
Managers
Title Age Since
Chief Executive Officer
63
12-12-31
Founder
77
03-01-23
Founder
75
03-01-23
Members of the board
Title Age Since
Chairman
70
16-12-31
Director/Board Member
58
23-05-31
Director/Board Member
56
-
More insiders
Date
Price
Change
Volume
24-04-29
199
+0.76%
109,223
24-04-26
197.5
+1.96%
121,787
24-04-25
193.7
-0.92%
138,091
24-04-24
195.5
+3.77%
232,942
24-04-23
188.4
+2.06%
226,319
Delayed Quote
Nasdaq Stockholm, April 29, 2024 at 11:29 am EDT
More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
More about the company
Average target price
366.2
SEK
Spread / Average Target
+84.02%
Consensus
1st Jan change
Capi.
-25.69% 1.59B +1.77% 42.75B +47.70% 41.61B +12.24% 41.34B -8.83% 26.59B +7.44% 25.49B -23.01% 18.12B +30.56% 12.24B -1.82% 11.76B +8.35% 11B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1